ChemicalBook >> CAS DataBase List >>GDC-0853
GDC-0853
- CAS No.
- 1434048-34-6
- Chemical Name:
- GDC-0853
- Synonyms
- GDC0853;CS-2241;EOS-61209;FENEBRUTINIB;GDC-0853;GDC 0853;GDC-0853 (RG7845);GDC-0853/Fenebrutinib;FENEBRUTINIB (GDC-0853);inhibit,Inhibitor,GDC0853,GDC 0853,Fenebrutinib,Btk,Bruton tyrosine kinase;2-1,6-Dihydro-3'-(hydroxymethyl)-1-methyl-5-5-(2S)-2-methyl-4-(3-oxetanyl)piperazin-1-ylpyridin-2-ylamino-6-oxo3,4'-bipyridin-2'-yl-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta4,5pyrrolo1,2-apyrazin-1(6H)-one
- CBNumber:
- CB33142405
- Molecular Formula:
- C37H44N8O4
- Molecular Weight:
- 664.8
- MDL Number:
- MFCD30489729
- MOL File:
- 1434048-34-6.mol
Last updated:2023-09-20 16:43:00
| Boiling point | 936.3±65.0 °C(Predicted) |
|---|---|
| Density | 1.42±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility |
DMF:20.0(Max Conc. mg/mL);30.08(Max Conc. mM) DMSO:17.0(Max Conc. mg/mL);25.57(Max Conc. mM) DMSO:PBS (pH 7.2) (1:2):0.33(Max Conc. mg/mL);0.5(Max Conc. mM) Ethanol:5.0(Max Conc. mg/mL);7.52(Max Conc. mM) |
| form | A crystalline solid |
| pka | 13.15±0.10(Predicted) |
| FDA UNII | E9L2885WUL |
GDC-0853 price More Price(17)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 21346 | GDC-0853 ≥98% | 1434048-34-6 | 1mg | $39 | 2024-03-01 | Buy |
| Cayman Chemical | 21346 | GDC-0853 ≥98% | 1434048-34-6 | 5mg | $180 | 2024-03-01 | Buy |
| Cayman Chemical | 21346 | GDC-0853 ≥98% | 1434048-34-6 | 10mg | $340 | 2024-03-01 | Buy |
| Cayman Chemical | 21346 | GDC-0853 ≥98% | 1434048-34-6 | 25mg | $647 | 2023-06-20 | Buy |
| TRC | F247550 | Fenebrutinib | 1434048-34-6 | 5mg | $440 | 2021-12-16 | Buy |
GDC-0853 Chemical Properties,Uses,Production
Description
GDC-0853 is an orally bioavailable, selective, and reversible Bruton’s tyrosine kinase (BTK) inhibitor with IC50s ranging from 2-9 nM for basophil activation, B cell receptor activation, and constitutive p-BTK activity in whole blood lysates. In rats, treatment for longer than 7 days leads to pancreatic toxicity but it does not occur in mice or dogs, even at higher doses. Formulations containing GDC-0853 were well-tolerated in Phase I clinical trials and are in additional clinical trials for rheumatoid arthritis, lupus erythematosus, lymphoma, and leukemia.
Uses
Fenebrutinib is a selective and reversible oral small-molecular BTK inhibitor for the treatment of rheumatoid arthritis and systemic lupus erythematosus.
GDC-0853 Preparation Products And Raw materials
Raw materials
Preparation Products
Global( 73)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32480 | 60 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
| career henan chemical co | +86-0371-86658258 15093356674; | factory@coreychem.com | China | 29826 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6313 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10523 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6393 | 58 |
| LEAP CHEM CO., LTD. | +86-852-30606658 | market18@leapchem.com | China | 24738 | 58 |
| Aladdin Scientific | +1-833-552-7181 | sales@aladdinsci.com | United States | 52927 | 58 |
| Amadis Chemical Company Limited | 571-89925085 | sales@amadischem.com | China | 131981 | 58 |
| Shanghai XingMo Biotechnology Co., Ltd. | 13524779951 | 2075692521@qq.com | China | 309 | 55 |
(S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one
GDC0853
EOS-61209
GDC-0853 (RG7845)
GDC-0853;GDC 0853
FENEBRUTINIB (GDC-0853)
FENEBRUTINIB
CS-2241
GDC-0853/Fenebrutinib
2H-Cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one, 2-[1,6-dihydro-3'-(hydroxymethyl)-1-methyl-5-[[5-[(2S)-2-methyl-4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-oxo[3,4'-bipyridin]-2'-yl]-3,4,7,8-tetrahydro-7,7-dimethyl-
2-[1,6-Dihydro-3'-(hydroxymethyl)-1-methyl-5-[[5-[(2S)-2-methyl-4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-oxo[3,4'-bipyridin]-2'-yl]-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one
inhibit,Inhibitor,GDC0853,GDC 0853,Fenebrutinib,Btk,Bruton tyrosine kinase
2-1,6-Dihydro-3'-(hydroxymethyl)-1-methyl-5-5-(2S)-2-methyl-4-(3-oxetanyl)piperazin-1-ylpyridin-2-ylamino-6-oxo3,4'-bipyridin-2'-yl-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta4,5pyrrolo1,2-apyrazin-1(6H)-one
(S)-2-(3'-(Hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one
2-1,6-Dihydro-3'-(hydroxymethyl)-1-methyl-5-5-(2S)-2-methyl-4-(3-oxetanyl)piperazin-1-ylpyridin-2-ylamino-6-oxo3,4'-bipyridin-2'-yl-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta4,5pyrrolo1,2-apyrazin-1(6H)-one
1434048-34-6